SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$456M
Q3 2020
Positions
24
Filings on Record
31
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Lion Point Capital, LP reported $456M in U.S.-listed holdings across 24 positions for Q3 2020.

The portfolio is heavily concentrated: CSIQ alone accounts for 25.6% of reported value.

Compared with Q2 2020, the fund opened 2 new positions and exited 2.

Portfolio Metrics

Turnover
+17.8%
vs prior filed quarter
Top-10 Concentration
+81.9%
share of reported value
Largest Position
+25.6%
Canadian Solar
New / Exited
2 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.9%Other: 8.8%ETP: 5.2%
  • Common Stock · 85.9% · $392M
  • Other · 8.8% · $40M
  • ETP · 5.2% · $24M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MARINUS PHARMACEUTICALS INCNEW+2.72M2.72M+$35M$35M
ISHARES TRNEW+93.0K93.0K+$14M$14M
MRNSUSDMARINUS PHARMACEUTICALS INCSOLD OUT−10.87M0−$28M$0
PDCEUSDPDC ENERGY INCSOLD OUT−1.47M0−$18M$0
TGTXTG THERAPEUTICS INCADDED+429.9K1.33M+$18M$36M
CSIQCANADIAN SOLAR INCTRIMMED−957.6K3.33M+$34M$117M
LSCCLATTICE SEMICONDUCTOR CORPADDED+40.0K458.2K+$1M$13M
DRRXEURDURECT CORPHELD−862.6K17.73M−$13M$30M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

22 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CSIQCANADIAN SOLAR INChistory →COM25.62%$117M3.33M
2ACHCACADIA HEALTHCARE COMPANY INhistory →COM10.08%$46M1.56M
3TGTXTG THERAPEUTICS INChistory →COM7.79%$36M1.33M
4MARINUS PHARMACEUTICALS INCCOM NEW7.66%$35M2.72M
5DRRXEURDURECT CORPhistory →COM6.65%$30M17.73M
6LIBERTY GLOBAL PLCSHS CL A · SHS CL C5.87%$27M1.27M
7SWCHFSIERRA WIRELESS INChistory →COM5.25%$24M2.14M
8ARCONIC CORPORATIONCOM4.88%$22M1.17M
9AAALCOA CORPhistory →COM4.33%$20M1.70M
10PRSPPERSPECTA INChistory →COM3.84%$18M900.0K
11ISHARES TRRUSSELL 2000 ETF3.06%$14M93.0K
12LSCCLATTICE SEMICONDUCTOR CORPhistory →COM2.91%$13M458.2K
13BATLBATTALION OIL CORPhistory →COM2.49%$11M1.44M
14KINIKSA PHARMACEUTICALS LTDCOM CL A1.67%$8M495.7K
15LUMOS PHARMA INCCOM1.23%$6M407.2K
16LOGCUSDLOGICBIO THERAPEUTICS INCCOM1.00%$5M500.0K
17OUTFRONT MEDIA INCCOM0.96%$4M300.0K
18SCOR1EURCOMSCORE INCCOM0.86%$4M1.92M
19EXTREXTREME NETWORKS INCCOM0.72%$3M811.8K
20AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.47%$2M300.0K
21OPES ACQUISITION CORPUNIT 03/07/20230.32%$1M83.4K
22OVVOVINTIV INCCOM0.16%$735,00090.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.